Stock Price Forecast

Feb. 7, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Adicet Bio Inc chart...

About the Company

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

CEO

Chen Schor

Exchange

NASDAQ

Website

www.adicetbio.com

$39M

Total Revenue

86

Employees

$363M

Market Capitalization

-11.13

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ACET News

Adicet Bio

7d ago, source: Forbes

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was ...

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

13d ago, source: MSN

Adicet Bio, Inc. (ACET) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's ...

Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

6d ago, source: Yahoo

REDWOOD CITY, Calif. & BOSTON, February 01, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell ...

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

7d ago, source: Benzinga.com

Adicet Bio, Inc. ACET, a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January ...

Adicet Bio Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

7d ago, source: Yahoo Finance

REDWOOD CITY, Calif. & BOSTON, February 01, 2023--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell ...

Adicet Bio Inc (ACET)

5d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

6d ago, source: Joplin Globe

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...